EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 290 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New on NCI’s Websites for January 2020 January 2, 2020 News digest – HPV vaccine, 1 million breast screenings missed and... October 3, 2020 How Music Can Help You Cope During Cancer: An Expert Perspective October 5, 2021 Can Eating Soy Cause Breast Cancer? October 19, 2021 Load more HOT NEWS For Children with Retinoblastoma, Disparities Seen across the Globe ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΕΟΥΣ Mapping Cancer Genomic Evolution Offers Insights into Tumor Development French Senate Committee Backs ESMO Call to Revise EU Regulation to...
